Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.
We report a patient with very advanced myelofibrosis and huge splenomegaly who showed a complete hematological response to low dose thalidomide with reversal of splenomegaly and bone narrow fibrosis after 30 months of the treatment.
Berrebi
Alain
A
Hematology Institute, Kaplan Medical Center, Rehovot, Israel 76100. alain_b@clalit.org.il
Feldberg
Edit
E
Spivak
Irena
I
Shvidel
Lev
L
D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D001803:Blood Transfusion; D001853:Bone Marrow / Q000473:pathology; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005474:Fluoxymesterone / Q000008:administration & dosage / Q000627:therapeutic use; D005492:Folic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D012074:Remission Induction; D013163:Splenomegaly / Q000209:etiology; D013792:Thalidomide / Q000008:administration & dosage* / Q000627:therapeutic use; D014803:Vitamin B Complex / Q000008:administration & dosage / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D014803:Vitamin B Complex; D013792:Thalidomide; D005492:Folic Acid; D005474:Fluoxymesterone; D011241:Prednisone